AR089130A1 - FORMAS DE DOSIS FARMACEUTICA QUE COMPRENDEN POLI(e-CAPROLACTONA) Y OXIDO DE POLIETILENO - Google Patents
FORMAS DE DOSIS FARMACEUTICA QUE COMPRENDEN POLI(e-CAPROLACTONA) Y OXIDO DE POLIETILENOInfo
- Publication number
- AR089130A1 AR089130A1 ARP120104624A ARP120104624A AR089130A1 AR 089130 A1 AR089130 A1 AR 089130A1 AR P120104624 A ARP120104624 A AR P120104624A AR P120104624 A ARP120104624 A AR P120104624A AR 089130 A1 AR089130 A1 AR 089130A1
- Authority
- AR
- Argentina
- Prior art keywords
- extended release
- dosage form
- caprolactone
- solid
- polyethylene oxide
- Prior art date
Links
- 229920003171 Poly (ethylene oxide) Polymers 0.000 title abstract 3
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 title abstract 3
- 238000013265 extended release Methods 0.000 abstract 9
- 239000000203 mixture Substances 0.000 abstract 9
- 239000002552 dosage form Substances 0.000 abstract 4
- 239000007787 solid Substances 0.000 abstract 4
- 238000009472 formulation Methods 0.000 abstract 3
- 239000011159 matrix material Substances 0.000 abstract 3
- 239000013543 active substance Substances 0.000 abstract 2
- 150000004677 hydrates Chemical class 0.000 abstract 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 abstract 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000007909 solid dosage form Substances 0.000 abstract 2
- WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 abstract 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical group CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 abstract 1
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 abstract 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 abstract 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 abstract 1
- 229960004126 codeine Drugs 0.000 abstract 1
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 abstract 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 abstract 1
- 229940049654 glyceryl behenate Drugs 0.000 abstract 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 abstract 1
- 229960000240 hydrocodone Drugs 0.000 abstract 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 abstract 1
- 229960001410 hydromorphone Drugs 0.000 abstract 1
- 229960005181 morphine Drugs 0.000 abstract 1
- 229960005297 nalmefene Drugs 0.000 abstract 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 abstract 1
- 229960004127 naloxone Drugs 0.000 abstract 1
- 229960003086 naltrexone Drugs 0.000 abstract 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 abstract 1
- 239000003401 opiate antagonist Substances 0.000 abstract 1
- 239000000014 opioid analgesic Substances 0.000 abstract 1
- 229960002085 oxycodone Drugs 0.000 abstract 1
- 229960005118 oxymorphone Drugs 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161569193P | 2011-12-09 | 2011-12-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR089130A1 true AR089130A1 (es) | 2014-07-30 |
Family
ID=47522734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120104624A AR089130A1 (es) | 2011-12-09 | 2012-12-10 | FORMAS DE DOSIS FARMACEUTICA QUE COMPRENDEN POLI(e-CAPROLACTONA) Y OXIDO DE POLIETILENO |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20150265536A1 (enExample) |
| EP (1) | EP2787978B1 (enExample) |
| JP (1) | JP6144274B2 (enExample) |
| CN (2) | CN104010630A (enExample) |
| AR (1) | AR089130A1 (enExample) |
| AU (1) | AU2012327231B2 (enExample) |
| CA (1) | CA2858868C (enExample) |
| ES (1) | ES2603278T3 (enExample) |
| TW (1) | TW201336529A (enExample) |
| WO (1) | WO2013084059A1 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1429739A1 (en) | 2001-09-21 | 2004-06-23 | Egalet A/S | Polymer release system |
| EP1429744A1 (en) | 2001-09-21 | 2004-06-23 | Egalet A/S | Morphine polymer release system |
| US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| DE602004031096D1 (de) | 2003-03-26 | 2011-03-03 | Egalet As | Morphin-system mit kontrollierter freisetzung |
| DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
| DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| CA2687192C (en) | 2007-06-04 | 2015-11-24 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
| US8383152B2 (en) | 2008-01-25 | 2013-02-26 | Gruenenthal Gmbh | Pharmaceutical dosage form |
| TWI524904B (zh) | 2008-05-09 | 2016-03-11 | 歌林達股份有限公司 | 製備醫藥用固體劑型，尤指錠劑之方法，及製備固體劑型，尤指錠劑之前驅物之方法 |
| NZ594207A (en) | 2009-02-06 | 2013-03-28 | Egalet Ltd | Immediate release composition resistant to abuse by intake of alcohol |
| NZ597283A (en) | 2009-06-24 | 2013-07-26 | Egalet Ltd | Controlled release formulations |
| JP5667183B2 (ja) | 2009-07-22 | 2015-02-12 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 加熱溶融押出成型した制御放出性投与剤型 |
| NZ596668A (en) | 2009-07-22 | 2013-09-27 | Gruenenthal Chemie | Oxidation-stabilized tamper-resistant dosage form |
| MX2013002293A (es) | 2010-09-02 | 2013-05-09 | Gruenenthal Gmbh | Forma de dosificacion resistente a alteracion que comprende un polimero anionico. |
| ES2486791T3 (es) | 2010-09-02 | 2014-08-19 | Grünenthal GmbH | Forma de dosificación resistente a la manipulación que comprende una sal inorgánica |
| PE20141650A1 (es) | 2011-07-29 | 2014-11-22 | Gruenenthal Chemie | Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco |
| EA201400172A1 (ru) | 2011-07-29 | 2014-06-30 | Грюненталь Гмбх | Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства |
| WO2013127831A1 (en) | 2012-02-28 | 2013-09-06 | Grünenthal GmbH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
| ES2692944T3 (es) | 2012-04-18 | 2018-12-05 | Grünenthal GmbH | Forma de dosificación farmacéutica resistente a la manipulación y resistente a la descarga rápida de la dosis |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| US9549899B2 (en) | 2012-07-06 | 2017-01-24 | Egalet Ltd. | Abuse deterrent pharmaceutical compositions for controlled release |
| BR112015026549A2 (pt) | 2013-05-29 | 2017-07-25 | Gruenenthal Gmbh | forma de dosagem à prova de violação contendo uma ou mais partículas |
| US9737490B2 (en) | 2013-05-29 | 2017-08-22 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile |
| AU2014289187B2 (en) | 2013-07-12 | 2019-07-11 | Grunenthal Gmbh | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
| CA2919892C (en) | 2013-08-12 | 2019-06-18 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| AU2014356581C1 (en) | 2013-11-26 | 2020-05-28 | Grunenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| MX2016014738A (es) | 2014-05-12 | 2017-03-06 | Gruenenthal Gmbh | Formulacion en capsula de liberacion inmediata resistente a alteraciones que comprende tapentadol. |
| CN106456550A (zh) | 2014-05-26 | 2017-02-22 | 格吕伦塔尔有限公司 | 避免乙醇剂量倾泻的多颗粒 |
| DK3169315T3 (da) | 2014-07-17 | 2020-08-10 | Pharmaceutical Manufacturing Res Services In | Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse |
| US9132096B1 (en) * | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
| EP3209282A4 (en) | 2014-10-20 | 2018-05-23 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| CN107205943A (zh) * | 2014-12-08 | 2017-09-26 | 德威洛克制药有限公司 | 纳洛酮单剂和多层片剂 |
| BR112017021475A2 (pt) | 2015-04-24 | 2018-07-10 | Gruenenthal Gmbh | forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente |
| CA2998259A1 (en) | 2015-09-10 | 2017-03-16 | Grunenthal Gmbh | Protecting oral overdose with abuse deterrent immediate release formulations |
| CN118975972A (zh) | 2015-10-23 | 2024-11-19 | 林德拉治疗公司 | 用于治疗剂缓释的胃驻留系统及其使用方法 |
| BR112018011636B1 (pt) | 2015-12-08 | 2024-03-12 | Lyndra Therapeutics, Inc | Sistema de residência gástrico para liberação sustentada de um agente terapêutico |
| EP3181124A1 (en) * | 2015-12-16 | 2017-06-21 | Universität Basel | Abuse deterrent pharmaceutical dosage forms |
| CN119925721A (zh) | 2016-05-27 | 2025-05-06 | 林德拉治疗公司 | 用于胃驻留系统的材料结构 |
| CN110022861B (zh) | 2016-09-30 | 2024-06-28 | 林德拉治疗公司 | 用于金刚烷类药物缓释的胃驻留系统 |
| AU2018279853B2 (en) | 2017-06-09 | 2024-07-04 | Lyndra Therapeutics, Inc. | Gastric residence systems with release rate-modulating films |
| IL273627B2 (en) | 2017-12-20 | 2025-03-01 | Purdue Pharma Lp | Morphine sulfate dosage forms for abuse deterrence |
| WO2023145869A1 (ja) * | 2022-01-31 | 2023-08-03 | 住友精化株式会社 | 製剤用組成物の製造方法及び製剤の製造方法 |
| WO2023145871A1 (ja) * | 2022-01-31 | 2023-08-03 | 住友精化株式会社 | 製剤用組成物の製造方法及び製剤の製造方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2557459B1 (fr) * | 1984-01-02 | 1986-05-30 | Lhd Lab Hygiene Dietetique | Matrice inerte a base de polycaprolactone pour administration orale d'un medicament, et procede de preparation de la forme galenique comprenant cette matrice |
| FR2701152B1 (fr) | 1993-02-03 | 1995-03-10 | Digipress Sa | Procédé de fabrication d'un disque maître pour la réalisation d'une matrice de pressage notamment de disques optiques, matrice de pressage obtenue par ce procédé et disque optique obtenu à partir de cette matrice de pressage. |
| EP0950689B1 (en) * | 1996-11-05 | 2004-10-06 | NOVAMONT S.p.A. | Biodegradable polymeric compositions comprising starch and a thermoplastic polymer |
| SI1299104T1 (sl) * | 2000-02-08 | 2009-10-31 | Euro Celtique Sa | Oralne formulacije opioidnih agonistov, varne pred zlorabo |
| US20020007013A1 (en) * | 2000-05-16 | 2002-01-17 | Cohen Gordon Mark | Compositions containing elastomeric ethylene or (meth)acrylic ester copolymers |
| CN100500130C (zh) * | 2003-01-23 | 2009-06-17 | 株式会社太平洋 | 缓释制剂及其制备方法 |
| BRPI0408323A (pt) * | 2003-03-14 | 2006-03-07 | Nirmal Mulye | processo para a preparação de compimidos de liberação prolongada |
| US20060165790A1 (en) * | 2003-06-27 | 2006-07-27 | Malcolm Walden | Multiparticulates |
| DE102005005446A1 (de) * | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| US20070014846A1 (en) * | 2003-10-10 | 2007-01-18 | Lifecycle Pharma A/S | Pharmaceutical compositions comprising fenofibrate and atorvastatin |
| ES2324719T3 (es) * | 2004-02-23 | 2009-08-13 | Euro-Celtique S.A. | Dispositivo de administracion transdermica de opioides con resistencia al abuso. |
| TW201509943A (zh) | 2004-03-30 | 2015-03-16 | Euro Celtique Sa | 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝 |
| BRPI0609910A2 (pt) * | 2005-05-10 | 2010-05-11 | Novartis Ag | composições farmacêuticas de famciclovir de liberação modificada |
| EP1968539A2 (en) * | 2005-12-13 | 2008-09-17 | Biodelivery Sciences International, Inc. | Abuse resistant transmucosal drug delivery device |
| SA07280459B1 (ar) * | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
| NZ592276A (en) * | 2008-09-18 | 2012-12-21 | Purdue Pharma Lp | PHARMACEUTICAL DOSAGE FORMS COMPRISING POLY(epsilon-CAPROLACTONE) AND AN OPIOID |
-
2012
- 2012-12-07 US US14/363,004 patent/US20150265536A1/en not_active Abandoned
- 2012-12-07 EP EP12813099.4A patent/EP2787978B1/en active Active
- 2012-12-07 ES ES12813099.4T patent/ES2603278T3/es active Active
- 2012-12-07 CN CN201280059890.2A patent/CN104010630A/zh active Pending
- 2012-12-07 JP JP2014545381A patent/JP6144274B2/ja active Active
- 2012-12-07 CN CN201710933357.9A patent/CN107854434A/zh active Pending
- 2012-12-07 CA CA2858868A patent/CA2858868C/en active Active
- 2012-12-07 TW TW101146199A patent/TW201336529A/zh unknown
- 2012-12-07 AU AU2012327231A patent/AU2012327231B2/en active Active
- 2012-12-07 WO PCT/IB2012/002681 patent/WO2013084059A1/en not_active Ceased
- 2012-12-10 AR ARP120104624A patent/AR089130A1/es not_active Application Discontinuation
-
2019
- 2019-10-08 US US16/596,136 patent/US20200170954A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2787978B1 (en) | 2016-09-21 |
| US20150265536A1 (en) | 2015-09-24 |
| CN104010630A (zh) | 2014-08-27 |
| CN107854434A (zh) | 2018-03-30 |
| AU2012327231A1 (en) | 2013-06-27 |
| US20200170954A1 (en) | 2020-06-04 |
| JP6144274B2 (ja) | 2017-06-07 |
| CA2858868C (en) | 2017-08-22 |
| WO2013084059A1 (en) | 2013-06-13 |
| ES2603278T3 (es) | 2017-02-24 |
| AU2012327231B2 (en) | 2015-09-24 |
| JP2015500273A (ja) | 2015-01-05 |
| TW201336529A (zh) | 2013-09-16 |
| CA2858868A1 (en) | 2013-06-13 |
| EP2787978A1 (en) | 2014-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR089130A1 (es) | FORMAS DE DOSIS FARMACEUTICA QUE COMPRENDEN POLI(e-CAPROLACTONA) Y OXIDO DE POLIETILENO | |
| AR095160A1 (es) | Formulaciones farmacéuticas a prueba de alteraciones | |
| JP2015044834A5 (enExample) | ||
| JP2011137020A5 (enExample) | ||
| AR088250A1 (es) | Forma de dosificacion farmaceutica oral resistente a alteracion comprendiendo agonista opioide y antagonista opioide | |
| AR095343A1 (es) | Cápsula resistente a su uso indebido por administración parenteral de principios activos | |
| JP2016014040A5 (enExample) | ||
| PE20220581A1 (es) | Composicion farmaceutica para suministro nasal | |
| EA032906B1 (ru) | Твердая лекарственная форма с контролируемым высвобождением и способы ее получения и применения | |
| RU2013117274A (ru) | Композиции и способы для смягчения дыхательной недостаточности, вызванной передозировкой опиоидов | |
| PE20141671A1 (es) | Forma de dosis farmaceutica oral a prueba de manipulacion que comprende un agente antagonista y/o repelente opioide, oxido de polialquileno y un polimero anionico | |
| EA201400246A1 (ru) | Новая, не допускающая злоупотребления фармацевтическая композиция для лечения опиоидной зависимости | |
| AR084620A1 (es) | Una combinacion de un agonista opiaceo y un antagonista opiaceo en el tratamiento de la enfermedad de parkinson | |
| AR092820A1 (es) | Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides, unidad de dosis, kit | |
| PE20190391A1 (es) | Formas de dosificacion del tapentadol novedosas y potentes | |
| MX2013008225A (es) | Composicion farmaceutica que comprende agonistas de opioide y antagonista secuestrado. | |
| CO6341547A2 (es) | Uso de antagonistas opioides para el tratamiento de retencion urinaria | |
| BR112012024019A2 (pt) | forma de dosagem de liberação controlada, e, método para liberar uma droga | |
| JP2013540807A5 (enExample) | ||
| DOP2012000264A (es) | Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan | |
| CY1124016T1 (el) | Φαρμακοτεχνικες μορφες οπιοειδων | |
| RU2016123972A (ru) | Применение антагониста опиоидных рецепторов с к-активностью и вортиоксетина для лечения депрессивного расстройства с меланхолическими признаками | |
| NZ603170A (en) | Combination of active loaded granules with additional actives | |
| JP2013537915A5 (enExample) | ||
| PH12016500666A1 (en) | Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |